|ENVISION HEALTHCARE CORP filed this Form 8-K on 10/31/2017|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 31, 2017
ENVISION HEALTHCARE CORPORATION
(Exact Name of Registrant as Specified in its Charter)
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02. Results of Operations and Financial Condition
On October 31, 2017, Envision Healthcare Corporation (the "Company") issued a press release, announcing its financial results for the three and nine months ended September 30, 2017. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure
On October 31, 2017, the Company issued a press release, the text of which is set forth as Exhibit 99.
Item 8.01. Other Events.
In the press release described in Item 2.02, the Company announced that its Board of Directors has unanimously decided to initiate a full review of a broad range of strategic alternatives to enhance shareholder value.
Item 9.01. Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 31, 2017
INDEX TO EXHIBITS